Why the study?
Does combined colestipol-niacin therapy improve angiographic outcomes (nonprogression and regression of coronary atherosclerosis) in coronary bypass subjects?
Does combined colestipol-niacin therapy improve angiographic outcomes (nonprogression and regression of coronary atherosclerosis) in coronary bypass subjects?
Answers are grounded in this paper and cite their sources.
Long-term (4-year) lipid-lowering therapy with colestipol-niacin significantly reduces progression and increases regression of coronary atherosclerosis in post-bypass patients.
The Cholesterol Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing combined colestipol-niacin therapy in 162 subjects. Two-year results (CLAS-I) showed decreased atherosclerosis progression and increased regression. We now describe a subgroup of 103 subjects treated for 4 years (CLAS-II). Changes in blood lipid, lipoproteincholesterol, and apolipoprotein levels were maintained, and at 4 years significantly more drug-treated subjects demonstrated nonprogression (52% drug- vs 15% placebo-treated) and regression (18% drug- vs 6% placebo-treated) in native coronary artery lesions. Significantly fewer drug-treated subjects developed new lesions in native coronary arteries (14% drug- vs 40% placebo-treated) and bypass grafts (16% drug- vs 38% placebo-treated). These results confirm CLAS-I findings and indicate that regression can continue for 4 years. They reaffirm the need for early initiation of vigorous long-term lipid lowering therapy in coronary bypass subjects. (JAMA. 1990;264:3013-3017)
No takes yet. Share an insight, caveat, or question.
Linda Cashin-Hemphill (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: